Skip to main content
Top
Published in: Clinical and Experimental Medicine 2/2018

01-05-2018 | Original Article

Expression of MIF and TNFA in psoriatic arthritis: relationship with Th1/Th2/Th17 cytokine profiles and clinical variables

Authors: L. A. Bautista-Herrera, U. De la Cruz-Mosso, R. Morales-Zambrano, G. D. Villanueva-Quintero, J. Hernández-Bello, M. G. Ramírez-Dueñas, E. Martínez-López, L. M. Brennan-Bourdon, C. J. Baños-Hernández, J. F. Muñoz-Valle

Published in: Clinical and Experimental Medicine | Issue 2/2018

Login to get access

Abstract

Psoriatic arthritis (PsA) is an autoimmune inflammatory disease associated with psoriasis. The cause of this pathology is still unknown, but research suggests the diseases are caused by a deregulated cytokine production. MIF is a cytokine associated with immunomodulation of Th1, Th2, and Th17 cytokine profiles in inflammatory diseases. Based on this knowledge, the aim of this study was to determine the association of MIF and TNFA expression with Th1, Th2, and Th17 cytokine profiles in serum levels of PsA patients. A cross-sectional study was performed in 50 PsA patients and 30 control subjects (CS). The cytokine profiles were quantified by BioPlex MagPix system and the mRNA expression levels by real-time PCR. TNFA mRNA expression was 138.81-folds higher in PsA patients than CS (p < 0.001). Regarding MIF mRNA expression, no significant differences were observed; however, a positive correlation was identified between MIF mRNA expression and PsA time of evolution (r = − 0.53, p = 0.009). An increase of Th1 (IFNγ: PsA = 37.1 pg/mL vs. CS = 17 pg/mL, p < 0.05; TNFα: PsA = 24.6 pg/mL vs. CS = 9.8 pg/mL, p < 0.0001) and Th17 cytokine profiles (IL-17: PsA = 6.4 pg/mL vs. CS = 2.7 pg/mL, p < 0.05; IL-22: PsA = 8.4 pg/mL vs. CS = 1.8 pg/mL, p < 0.001), were found in PsA patients. Th2 cytokines were not significantly different in both groups. In conclusion, a high expression of TNFA mRNA, as well as an increase of Th1 and Th17 cytokine profiles evaluated by IFNγ, TNFα, IL-17, and IL-22 cytokines, was observed in PsA patients.
Literature
1.
go back to reference Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Eng J Med. 2017;376:957–70.CrossRef Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Eng J Med. 2017;376:957–70.CrossRef
2.
go back to reference Gladman DD. Clinical features and diagnostic considerations in psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):569–79.CrossRefPubMed Gladman DD. Clinical features and diagnostic considerations in psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):569–79.CrossRefPubMed
4.
go back to reference Álvarez J, Peláez I, Sanin L, et al. Prevalence of musculoskeletal pain and rheumatic diseases in the southeastern region of Mexico. J Rheumatol. 2011;86:21–5. Álvarez J, Peláez I, Sanin L, et al. Prevalence of musculoskeletal pain and rheumatic diseases in the southeastern region of Mexico. J Rheumatol. 2011;86:21–5.
5.
go back to reference Bowcok A, Krueger J. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol. 2005;9:699–711.CrossRef Bowcok A, Krueger J. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol. 2005;9:699–711.CrossRef
7.
go back to reference Moll J, Wright V. Psoriatic arthritis. Sem Arthr Rheum. 1973;1:59–78. Moll J, Wright V. Psoriatic arthritis. Sem Arthr Rheum. 1973;1:59–78.
8.
go back to reference Morales-Zambrano RA, Bautista-Herrera LA, De la Cruz-Mosso U, et al. Macrophage migration inhibitory factor (MIF) promoter polymorphisms (− 794 CATT5-8 and − 173 G > C) association with MIF and TNFα in psoratic arthritis. Int J Clin Exp Med. 2014;7(9):2605–14.PubMedPubMedCentral Morales-Zambrano RA, Bautista-Herrera LA, De la Cruz-Mosso U, et al. Macrophage migration inhibitory factor (MIF) promoter polymorphisms (− 794 CATT5-8 and − 173 G > C) association with MIF and TNFα in psoratic arthritis. Int J Clin Exp Med. 2014;7(9):2605–14.PubMedPubMedCentral
9.
go back to reference Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003;3:791–800.CrossRefPubMed Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003;3:791–800.CrossRefPubMed
10.
go back to reference Llamas Covarrubias MA, Valle Y, Navarro Hernández RE, et al. Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course. Rheumatol Int. 2012;32:2307–11.CrossRefPubMed Llamas Covarrubias MA, Valle Y, Navarro Hernández RE, et al. Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course. Rheumatol Int. 2012;32:2307–11.CrossRefPubMed
11.
go back to reference Xue H, Yang Y, Zhang Y, et al. Macrophage migration inhibitory factor interacting with Th17 cells may be involved in the pathogenesis of autoimmune damage in Hashimoto´s Tiroiditis. Med Inflamm. 2015. doi:10.1155/2015/621072. Xue H, Yang Y, Zhang Y, et al. Macrophage migration inhibitory factor interacting with Th17 cells may be involved in the pathogenesis of autoimmune damage in Hashimoto´s Tiroiditis. Med Inflamm. 2015. doi:10.​1155/​2015/​621072.
12.
go back to reference De la Cruz Mosso U, Bucala R, Palafox-Sánchez CA, et al. Macrophage migration inhibitory factor: association of − 794 CATT5-8 and − 173 G > C polymorphisms with TNF-α in systemic lupus erythematosus. Hum Immunol. 2014;75(5):433–9.CrossRef De la Cruz Mosso U, Bucala R, Palafox-Sánchez CA, et al. Macrophage migration inhibitory factor: association of − 794 CATT5-8 and − 173 G > C polymorphisms with TNF-α in systemic lupus erythematosus. Hum Immunol. 2014;75(5):433–9.CrossRef
13.
go back to reference Shimizu T. Role of macrophage migration inhibitory factor (MIF) in the skin. J Dermatol. 2005;37(2):65–73. Shimizu T. Role of macrophage migration inhibitory factor (MIF) in the skin. J Dermatol. 2005;37(2):65–73.
14.
go back to reference Stojanovic I, Cvjeticanin T, Lazaroski S, et al. Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells. Immunology. 2009;126(1):74–83.CrossRefPubMedPubMedCentral Stojanovic I, Cvjeticanin T, Lazaroski S, et al. Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells. Immunology. 2009;126(1):74–83.CrossRefPubMedPubMedCentral
15.
go back to reference Das R, Moss JE, Robinson E, et al. Role of macrophage migration inhibitory factor in the Th2 immune response to epicutaneous sensitization. J Clin Immunol. 2011;31(4):666–80.CrossRefPubMedPubMedCentral Das R, Moss JE, Robinson E, et al. Role of macrophage migration inhibitory factor in the Th2 immune response to epicutaneous sensitization. J Clin Immunol. 2011;31(4):666–80.CrossRefPubMedPubMedCentral
16.
go back to reference Taylor W, Gladman DD, Helliwel P, et al. Classification criteria for psotiatic arthritis: development a new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.CrossRefPubMed Taylor W, Gladman DD, Helliwel P, et al. Classification criteria for psotiatic arthritis: development a new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.CrossRefPubMed
17.
go back to reference Belmonte-Serrano MA. Is the DAS28 the most adequate method to estimated activity in rheumatoid arthritis clinic considerations and simulations scenarios. Rheumatol Clin. 2008;4:183–90. Belmonte-Serrano MA. Is the DAS28 the most adequate method to estimated activity in rheumatoid arthritis clinic considerations and simulations scenarios. Rheumatol Clin. 2008;4:183–90.
18.
go back to reference Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162(1):156–9.CrossRefPubMed Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162(1):156–9.CrossRefPubMed
19.
go back to reference Livak KJ, Shmittgen TD. Analysis of relative gene expression data using realtime quantitative PCR and the 2 − DDCT method. Methods. 2001;25(4):402–8.CrossRefPubMed Livak KJ, Shmittgen TD. Analysis of relative gene expression data using realtime quantitative PCR and the 2 − DDCT method. Methods. 2001;25(4):402–8.CrossRefPubMed
20.
go back to reference Michalak SA, Pietrzak A, Szpietowsky CJ, et al. Cytokine network in psoriasis revisited. Eur Cytokine Netw. 2011;22(4):160–8. Michalak SA, Pietrzak A, Szpietowsky CJ, et al. Cytokine network in psoriasis revisited. Eur Cytokine Netw. 2011;22(4):160–8.
21.
go back to reference Diani M, Altomare G, Reali E. T cell responses in psoriasis and psoriatic arthritis. Autoimmune Rev. 2015;14(4):2686–92.CrossRef Diani M, Altomare G, Reali E. T cell responses in psoriasis and psoriatic arthritis. Autoimmune Rev. 2015;14(4):2686–92.CrossRef
22.
go back to reference Gang X, Wei H. Expression levels of IL–17 and TNF–α in degenerated lumbar intervertebral discs and their correlation. Exp Ther Med. 2016;11(6):2333–40.CrossRef Gang X, Wei H. Expression levels of IL–17 and TNF–α in degenerated lumbar intervertebral discs and their correlation. Exp Ther Med. 2016;11(6):2333–40.CrossRef
23.
go back to reference Gabr MA, Jing L, Sinclair SM. Interleukin-17 synergizes with IFNγ or TNFα to promote inflammatory mediator release and intercellular adhesion molecule-1 (ICAM-1) expression in human intervertebral disc cells. J Orthop Res. 2011;29(1):1–7.CrossRefPubMedPubMedCentral Gabr MA, Jing L, Sinclair SM. Interleukin-17 synergizes with IFNγ or TNFα to promote inflammatory mediator release and intercellular adhesion molecule-1 (ICAM-1) expression in human intervertebral disc cells. J Orthop Res. 2011;29(1):1–7.CrossRefPubMedPubMedCentral
24.
go back to reference Zaba LC, Cardinale I, Suárez Fariñas M, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204(13):3183–94.CrossRefPubMedPubMedCentral Zaba LC, Cardinale I, Suárez Fariñas M, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204(13):3183–94.CrossRefPubMedPubMedCentral
25.
go back to reference Raychaduri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;2:183–93.CrossRef Raychaduri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;2:183–93.CrossRef
27.
go back to reference Eyerich K, Dimartino V, Cavani A, et al. IL-17 and IL-22 in immunity: driving protection and pathology. Eur J Immunol. 2017;47(4):607–14.CrossRefPubMed Eyerich K, Dimartino V, Cavani A, et al. IL-17 and IL-22 in immunity: driving protection and pathology. Eur J Immunol. 2017;47(4):607–14.CrossRefPubMed
28.
go back to reference Mosmann TR, Coffman RL. Two types of murine T helper clones. Definition according to profiles of limphokine activities. J Immunol. 1986;136(7):2348–57.PubMed Mosmann TR, Coffman RL. Two types of murine T helper clones. Definition according to profiles of limphokine activities. J Immunol. 1986;136(7):2348–57.PubMed
29.
go back to reference Pasparakis M, Haase I, Nestle F. Mechanism regulating skin immunity and inflammation. Nature. 2014;14:289–301. Pasparakis M, Haase I, Nestle F. Mechanism regulating skin immunity and inflammation. Nature. 2014;14:289–301.
30.
go back to reference Hernandez-Bello J, Orego RE, Vazque VM. Aberrant expression of interleukin-10 in rheumatoid arthritis: relationship with IL10 haplotypes and autoantibodies. Cytokine. 2017;95:88–96.CrossRefPubMed Hernandez-Bello J, Orego RE, Vazque VM. Aberrant expression of interleukin-10 in rheumatoid arthritis: relationship with IL10 haplotypes and autoantibodies. Cytokine. 2017;95:88–96.CrossRefPubMed
31.
go back to reference Hayashi M, Yanava K, Umezawa Y, et al. IL-10 producing regulatory B cells are decreased in patient with psoriasis. J Dermatol. 2016;81(2):93–100. Hayashi M, Yanava K, Umezawa Y, et al. IL-10 producing regulatory B cells are decreased in patient with psoriasis. J Dermatol. 2016;81(2):93–100.
32.
go back to reference Wang YN, Zhang Y, Zhu Xian, et al. The beneficial effect of total glucosides of paeony of psoriathic arthritis links to circulating Tregs and Th1 Cell functions. Phyther Res. 2014;28:372–81.CrossRef Wang YN, Zhang Y, Zhu Xian, et al. The beneficial effect of total glucosides of paeony of psoriathic arthritis links to circulating Tregs and Th1 Cell functions. Phyther Res. 2014;28:372–81.CrossRef
33.
go back to reference Dolcino M, Ottria A, Barbieri A. Gene expression profiling in peripheral blood cells and synovial membranes of patients with psoriatic arthritis. PLoS One. 2015;10(6):e0128262.CrossRefPubMedPubMedCentral Dolcino M, Ottria A, Barbieri A. Gene expression profiling in peripheral blood cells and synovial membranes of patients with psoriatic arthritis. PLoS One. 2015;10(6):e0128262.CrossRefPubMedPubMedCentral
34.
go back to reference Gais P, Tiedje C, Altmayr F, et al. TRIF Signaling stimulates translation of TNF-a mRNA via prolonged activation of MK2. J Immunol. 2010;184:5842–8.CrossRefPubMed Gais P, Tiedje C, Altmayr F, et al. TRIF Signaling stimulates translation of TNF-a mRNA via prolonged activation of MK2. J Immunol. 2010;184:5842–8.CrossRefPubMed
35.
go back to reference Sullivan KE, Reddy ABM, Dietzmann K. Epigenetic regulation of tumor necrosis factor alpha. Mol Cel Biol. 2007;14:5147–60.CrossRef Sullivan KE, Reddy ABM, Dietzmann K. Epigenetic regulation of tumor necrosis factor alpha. Mol Cel Biol. 2007;14:5147–60.CrossRef
36.
go back to reference Steinhoff M, Meinhardt A, Steinhoff A. Evidence for a role of macrophage migration inhibitory factor in psoriatic skin disease. Br J Dermatol. 1999;141:1061–6.CrossRefPubMed Steinhoff M, Meinhardt A, Steinhoff A. Evidence for a role of macrophage migration inhibitory factor in psoriatic skin disease. Br J Dermatol. 1999;141:1061–6.CrossRefPubMed
37.
go back to reference Matia García I, Salgado Goytia L, Muñoz Valle JF, et al. Macrophage migration inhibitory factor promoter polymorphisms (− 794 catt5–8 a − 173 g > c): relationship with mRNA expression and soluble mif levels in young obese subjects. Dis Mark. 2015. doi:10.1155/2015/461208. Matia García I, Salgado Goytia L, Muñoz Valle JF, et al. Macrophage migration inhibitory factor promoter polymorphisms (− 794 catt5–8 a − 173 g > c): relationship with mRNA expression and soluble mif levels in young obese subjects. Dis Mark. 2015. doi:10.​1155/​2015/​461208.
38.
go back to reference Meyer Siegler K. Increased stability of macrophage migration inhibitory factor (MIF) in DU-145 prostate cancer cells. J Interferon Cytokine Res. 2000;20:769–78.CrossRef Meyer Siegler K. Increased stability of macrophage migration inhibitory factor (MIF) in DU-145 prostate cancer cells. J Interferon Cytokine Res. 2000;20:769–78.CrossRef
39.
go back to reference Onodera S, Hiroshi T, Kouji S, et al. High expression of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine. 2015;1:052–6. Onodera S, Hiroshi T, Kouji S, et al. High expression of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine. 2015;1:052–6.
40.
go back to reference Kingsley Gh, Kowalzyc A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012;51(8):1368–77.CrossRef Kingsley Gh, Kowalzyc A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012;51(8):1368–77.CrossRef
41.
go back to reference Roussou E, Bouraoui A. Real-life experience of using conventional disease-modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA). Retrospective analysis of the efficacy of methotrexate, sulfasalazine, and leflunomide in PsA in comparison to spondyloarthritides other than PsA and literature review of the use of conventional DMARDs in PsA. Eur J Rheumatol. 2017;4(1):1–10.CrossRefPubMedPubMedCentral Roussou E, Bouraoui A. Real-life experience of using conventional disease-modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA). Retrospective analysis of the efficacy of methotrexate, sulfasalazine, and leflunomide in PsA in comparison to spondyloarthritides other than PsA and literature review of the use of conventional DMARDs in PsA. Eur J Rheumatol. 2017;4(1):1–10.CrossRefPubMedPubMedCentral
42.
go back to reference Brennan-Bourdon LM, De la Cruz-Mosso U, Reyes-Castillo Z, et al. MIF and TNFa serum levels in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs: a cross-sectional study. Immunopharmacol Immunotoxicol. 2015;37(2):207–13.CrossRefPubMed Brennan-Bourdon LM, De la Cruz-Mosso U, Reyes-Castillo Z, et al. MIF and TNFa serum levels in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs: a cross-sectional study. Immunopharmacol Immunotoxicol. 2015;37(2):207–13.CrossRefPubMed
Metadata
Title
Expression of MIF and TNFA in psoriatic arthritis: relationship with Th1/Th2/Th17 cytokine profiles and clinical variables
Authors
L. A. Bautista-Herrera
U. De la Cruz-Mosso
R. Morales-Zambrano
G. D. Villanueva-Quintero
J. Hernández-Bello
M. G. Ramírez-Dueñas
E. Martínez-López
L. M. Brennan-Bourdon
C. J. Baños-Hernández
J. F. Muñoz-Valle
Publication date
01-05-2018
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 2/2018
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-017-0475-0

Other articles of this Issue 2/2018

Clinical and Experimental Medicine 2/2018 Go to the issue